Hydrocortisone,
does it really help with Correction of cortisol-deficiency fatigue and weakness and prevention of adrenal crisis in confirmed primary adrenal insufficiency?
research showsHydrocortisone is rated A because it is essential replacement therapy that restores missing cortisol, corrects deficiency-related fatigue and weakness, and helps prevent fatal adrenal crisis in confirmed primary adrenal insufficiency. A deliberate untreated placebo trial would be unethical, but the direct deficiency mechanism, long-established replacement effect, specialist guidelines, and crisis evidence are consistent. This is the same evidence axis as insulin glargine verdict 895 and levothyroxine verdict 923, which directly replace a confirmed hormone deficiency. It does not apply to unconfirmed so-called adrenal fatigue or ordinary fatigue without cortisol deficiency, and it is distinct from the bovine adrenal glandular in verdict 537.
ads claimThe claim that cortisol supplementation gives everyone more energy converts treatment of a confirmed deficiency into a general fatigue intervention. This A rating applies only to primary adrenal insufficiency established through appropriate cortisol, ACTH, and stimulation testing; it does not apply to a nonstandard diagnosis of adrenal fatigue.
Useful facts when choosing a product
- A common adult maintenance regimen for primary adrenal insufficiency totals 15 to 25 mg of hydrocortisone daily in two or three divided doses, with the largest dose in the morning, but the individualized prescription takes priority.
- Fever, infection, surgery, trauma, or vomiting can make the usual dose inadequate, so patients need a prearranged sick-day rule and emergency-injection plan.
- When aldosterone deficiency accompanies primary adrenal insufficiency, separate mineralocorticoid replacement such as fludrocortisone may be required; hydrocortisone alone should not be assumed to complete treatment.
- Overreplacement can cause weight gain, hypertension, hyperglycemia, bone loss, and Cushingoid changes, while abrupt cessation or failure to stress-dose can trigger adrenal crisis.
What the research actually shows
The 2016 guideline by Bornstein and colleagues recommends glucocorticoid replacement for all confirmed patients with primary adrenal insufficiency and suggests hydrocortisone 15 to 25 mg per day in two or three divided maintenance doses. It also directs immediate intravenous hydrocortisone when adrenal crisis is suspected and education about stress dosing and emergency injection. The 2021 review by Lousada and colleagues summarizes how infection, surgery, vomiting, failure to stress-dose, and glucocorticoid withdrawal can precipitate adrenal crisis and death. The 2014 randomized crossover study by Oksnes and colleagues did not compare replacement with no treatment; it maintained cortisol replacement in both oral and continuous-subcutaneous arms and suggested that more physiologic delivery may improve some vitality-related quality-of-life domains.
Why this is classified as A (88)
Confirmed primary adrenal insufficiency is a cortisol-deficiency disorder, and hydrocortisone directly replaces the missing hormone with effects on symptoms and survival risk. An untreated placebo trial is unethical, but pathophysiology, long clinical experience, specialist guidelines, and crisis evidence are strong and consistent. The causal certainty of deficiency replacement supports A, in line with the 86-point A rating for levothyroxine verdict 923, with a modest recalibration to 88 points. Overreplacement, stress dosing, and abrupt-withdrawal risks remain separate safety issues.
Counterpoint. Persistent fatigue during replacement should prompt review of dose and timing, mineralocorticoid status, anemia, thyroid disease, sleep disorders, depression, and other causes rather than unsupervised dose escalation. Use for energy enhancement in a person with normal cortisol function is outside this verdict.
Rejudgment record. Cross-check revision — Retained A because direct replacement of confirmed cortisol deficiency and prevention of adrenal crisis provide the same causal certainty as the 86-point A rating for levothyroxine verdict 923, while modestly recalibrating the score to 88; excluded nondeficient so-called adrenal fatigue
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Correction of cortisol-deficiency fatigue and weakness in confirmed primary adrenal insufficiency | A | This is essential direct hormone replacement, although imperfect reproduction of the circadian rhythm can leave residual fatigue. |
| Prevention of adrenal crisis in confirmed primary adrenal insufficiency | A | Daily replacement must be accompanied by stress dosing, emergency injection, education, and mineralocorticoid replacement when indicated. |
| Improvement of ordinary fatigue attributed to nondeficient, nonstandard 'adrenal fatigue' | ? | No eligible human efficacy literature supports hydrocortisone in this nonstandard category, which is outside the A-rated indication. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Bornstein SR et al. 2016 Endocrine Society guideline | Systematic evidence review and clinical practice guideline | Endocrine Society with European Society of Endocrinology and American Association for Clinical Chemistry cosponsorship | Maintenance glucocorticoid replacement, symptom monitoring, and adrenal-crisis treatment and prevention | Strongly recommended glucocorticoid replacement for all confirmed patients, with adult hydrocortisone 15 to 25 mg daily and immediate intravenous treatment during crisis. | Core recommendation defining scope and essential therapy; not treated as a randomized trial | |
| Lousada LM et al. 2021 | Clinical review of adrenal crisis and mortality | Academic review with no separate commercial funding reported | Adrenal-crisis triggers, emergency treatment, prevention, and mortality | Identified glucocorticoid withdrawal and failure to stress-dose as crisis triggers and immediate intravenous hydrocortisone and education as central management. | Evidence addressing a direct lethal clinical outcome and prevention scope | |
| Oksnes M et al. 2014 | Multicenter randomized crossover active-comparator trial | 33 | Academic centers in Norway and Sweden; detailed disclosures apply | ACTH, circadian cortisol, metabolism, quality of life, sleep, and safety | Both oral hydrocortisone and continuous infusion maintained replacement; infusion produced a more physiologic cortisol profile and improved some vitality-related quality-of-life measures. | Replacement-regimen comparison, not a test of essential therapy versus no treatment |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-21).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-21 · Corrections: none
Cite this verdict
[Chamgap] Hydrocortisone x correction of deficiency symptoms and prevention of adrenal crisis in primary adrenal insufficiency — Evidence Grade A·88. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/energy/hydrocortisone-primary-adrenal-insufficiency-fatigue-crisis-prevention/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.